For a patient awaiting a diagnosis, the scan or procedure is one stage in getting an answer. Its value depends on what follows: a reliable report, clinical interpretation, a clear explanation and an appropriate next step. Diagnostic recovery therefore requires capacity across the pathway, from referral to decision and onward care.<\/p>\n
NHS England\u2019s October 2026 Integrated Performance Report presents a mixed position. In July, 23.1% of patients on the reported diagnostic waiting list had waited more than six weeks, compared with 23.3% in June and 21.9% a year earlier. The monthly improvement matters, but access remained worse than the previous July. These are July figures presented to the October Board, rather than a measure of October performance. [1]<\/p>\n
The policy direction is understandable: deliver the activity already funded, use available facilities more effectively and avoid unnecessary testing. Within constrained budgets, this encourages providers to obtain greater patient benefit from existing resources. The operational trade-off is that additional tests create work in reporting, review and follow-up. Leaders need to establish whether those services can absorb the activity before committing to expansion.<\/p>\n
The national Diagnostic Waiting Times and Activity collection, covers 15 key groups of tests and procedures. Its waiting-time clock stops when the patient receives the test or procedure. It consequently cannot establish, on its own, how long patients wait for reports, explanations or subsequent treatment. The collection is a valuable access measure with a defined scope. [2]<\/p>\n
Imaging reporting has its own interval: from examination to a verified report becoming available to the referring clinician. NHS England\u2019s reporting guidance differentiates expectations by clinical urgency, setting and examination type. This reinforces the need to assess testing and reporting together, while recognising their different operational requirements. [3]<\/p>\n
Cancer pathways make the importance of communication explicit. The Faster Diagnosis Standard generally measures the interval to patients being informed of a cancer diagnosis or cancer being ruled out, with specific rules for exceptions. Completing an investigation alone does not demonstrate that this stage has been reached. [5]<\/p>\n
For provider and integrated care board leaders, the implication is to connect these measures. A shorter test queue can represent meaningful progress while a reporting or review queue grows elsewhere. Local assurance should show whether patients are reaching clinical decisions sooner.<\/p>\n
The Royal College of Radiologists\u2019 2025 census briefing for England, published in June 2026, estimates a 33% shortfall in the consultant clinical radiology workforce. It reports 9% growth in demand for complex computed tomography and magnetic resonance imaging, compared with 4.2% consultant workforce growth over the year. This is an estimated workforce shortfall, rather than a vacancy rate. [4]<\/p>\n
That evidence provides an external balance check on the Board\u2019s emphasis on capacity and utilisation. More scanning sessions cannot, by themselves, resolve a reporting constraint. The census concerns radiology; other diagnostic services require their own assessment of skills, availability and workload.<\/p>\n
A credible delivery plan should identify the people needed at each stage: acquiring images or undertaking procedures, preparing and processing samples, reporting findings, reviewing results and arranging onward care. It should allow for supervision, training, leave and the complexity of cases, rather than treating every appointment as equivalent.<\/p>\n
The College also calls for sustained recruitment, training and retention, and reduced reliance on costly short-term workforce measures. [4] Time-limited support may still address a defined backlog, but leaders should assess whether it adds net capacity, protects the substantive team and leaves a sustainable service after the arrangement ends.<\/p>\n
The Board report requires community diagnostic centres to deliver their funded 2026\/27 activity plans. It also calls for action on low utilisation in computed tomography, magnetic resonance imaging, non-obstetric ultrasound, echocardiography and endoscopy. All trusts are required to have a demand optimisation delivery plan incorporating the 12 Right Test, Right Time tests and local priorities. These are reported requirements, rather than evidence that every action has been completed. [1]<\/p>\n
The case for this approach is strong: unused capacity and clinically unnecessary investigations can consume resources that would otherwise improve access. A credible alternative reading is that apparently low utilisation may reflect constraints in staffing, equipment reliability, preparation or downstream services. The utilisation figure should prompt investigation of the cause before a remedy is chosen.<\/p>\n
Clinical leaders should therefore examine referral quality, the appropriateness and sequencing of investigations, cancellations and repeat testing alongside session use. Demand optimisation should preserve timely access to clinically indicated tests and provide referrers with a workable alternative when a different route is appropriate.<\/p>\n
The Board\u2019s cancer recovery actions specifically include histopathology turnaround. [1] For an endoscopy pathway requiring biopsy analysis, extra procedures need to be matched to sample processing, reporting and subsequent review. The practical question is whether the proposed change shortens the patient\u2019s route to a decision.<\/p>\n
NHS England\u2019s community diagnostic centre guidance already describes a broader service model: coordinated testing in as few visits as possible, timely reporting to referrers, appropriate digital connectivity and onward referral within agreed protocols. It also recognises that clinical responsibility for the patient journey remains with the original referring clinician. [6]<\/p>\n
That principle should inform decisions about additional clinical capacity<\/a>, including clinical insourcing. Before activity begins, the provider and delivery team should agree the service\u2019s scope and the responsibilities retained by the referring service. A contract for a test, a reporting service and a managed clinical pathway involve different obligations.<\/p>\n The agreement should specify who reviews referrals, verifies reports, escalates urgent or unexpected findings, communicates results and arranges further investigations or follow-up. It should also establish how receipt and action are confirmed, how information enters the patient record and who resolves outstanding cases when the service ends.<\/p>\n Digital access matters because the receiving clinician needs usable information in the systems supporting care. A report being issued is only one part of a safe handover. Providers should test the practical workflow before expansion, including the arrangements when systems fail or a receiving team is unavailable.<\/p>\n This is also a financial discipline. Assessing the complete episode can reveal reporting, coordination and follow-up costs that a price per test leaves outside the comparison.<\/p>\n Boards need a concise view of where delay is accumulating. Alongside the national diagnostic waiting measure, local oversight should track clinically appropriate reporting turnaround, overdue reports, time to clinical review and communication, and access to the next required stage. Clinical teams should agree thresholds and escalation arrangements for their pathways.<\/p>\n These measures should be examined by diagnostic service, urgency and patient group. Aggregate improvement cannot establish that a particular pathway is functioning well, or that patients facing communication, transport or accessibility barriers are benefiting equally.<\/p>\n Patient experience should form part of that assessment. People should understand when and how they will receive an explanation, who is responsible for the next step and whom to contact if it does not happen. Coordinating appointments where clinically appropriate can reduce repeated visits, but convenience must remain aligned with safe investigation and review.<\/p>\n For healthcare workers, recovery should also be assessed through workload, supervision and the time spent chasing incomplete information. For leadership teams, useful assurance would demonstrate that additional activity produces timely, documented decisions without creating unmanaged work elsewhere.<\/p>\n The immediate task is to locate the constraint in each priority pathway and match the response to it. That may mean more appointments, reporting capacity, better referral decisions, faster sample processing or protected review time. Each intervention needs named responsibilities, workable handovers and measures showing whether patients reach answers and onward care sooner.<\/p>\n NHS England\u2019s emphasis on funded delivery and better utilisation provides a necessary starting point. The next leadership decision is to connect that activity to the capacity required to complete care. Diagnostic recovery becomes more credible when the patient\u2019s progress, staff workload and full delivery cost are assessed together.<\/p>\n <\/p>\n <\/p>\n [1] NHS England. Integrated Performance Report, October 2026 Board meeting, pp. 37\u201340 (supplied Board paper; July 2026 performance).<\/a><\/p>\n [2] NHS England. Diagnostics waiting times and activity: DM01 Guidance, version 9.0, March 2026, sections 1 and 2.3.<\/a><\/p>\n [3] NHS England. Diagnostic imaging reporting turnaround times, August 2023.<\/a><\/p>\n [4] Royal College of Radiologists. 2025 census policy briefing: England, June 2026.<\/a><\/p>\n5. Make patient progress the test of recovery<\/h3>\n
What this means now<\/h3>\n
References<\/h3>\n